Axon Enterprise (NASDAQ:AXON) Cut to “Neutral” at Northcoast Research

Northcoast Research cut shares of Axon Enterprise (NASDAQ:AXON) from a buy rating to a neutral rating in a research report released on Wednesday, Marketbeat reports.

AXON has been the topic of several other reports. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. TD Cowen assumed coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. Needham & Company LLC boosted their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, JMP Securities boosted their price objective on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $561.31.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $513.22 on Wednesday. The firm has a market cap of $39.13 billion, a price-to-earnings ratio of 132.62, a price-to-earnings-growth ratio of 5.95 and a beta of 1.05. Axon Enterprise has a 1-year low of $265.32 and a 1-year high of $715.99. The firm’s fifty day moving average price is $619.94 and its 200 day moving average price is $517.11. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Insider Activity at Axon Enterprise

In other news, Director Julie A. Cullivan sold 1,261 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the transaction, the director now owns 2,392 shares of the company’s stock, valued at $1,631,487.52. This represents a 34.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,711 shares of company stock valued at $5,631,561. 6.10% of the stock is owned by insiders.

Institutional Trading of Axon Enterprise

Institutional investors and hedge funds have recently bought and sold shares of the business. Fourth Dimension Wealth LLC acquired a new stake in Axon Enterprise during the 4th quarter worth approximately $30,000. New Wave Wealth Advisors LLC acquired a new stake in Axon Enterprise during the 4th quarter worth approximately $40,000. Y.D. More Investments Ltd acquired a new stake in Axon Enterprise during the 4th quarter worth approximately $45,000. Elequin Capital LP acquired a new stake in Axon Enterprise during the 4th quarter worth approximately $46,000. Finally, Prestige Wealth Management Group LLC increased its position in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.